Lecture 2- Motor Neurone Disease Flashcards

1
Q

Onset of MND

A

50-60 years of age, onset rarer as you age

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

lifetime risk of MND

A

1 in 300

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

symptoms of MND

A
  • loss of motor neuron circuitry- upper (motor cortex) and lower (brainstem)
  • loss of voluntary motor function in bulbar, upper limbs, lower limbs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

regions of motor neuron loss

A

bulbar- speech, swallowing, face muscle, eye movement
upper limbs- paralysis and muscle wasting in hands, arms, chest
lower limbs- paralysis and muscle wasting in legs, trunk

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

ALS functional rating scale

A

monitors loss of function over time by asking same questions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

respiratory function

A

loss of function is 100% fatal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

motor neuron degeneration

A

selective death of motor neurons, no transmission through circuitry, loss of muscle movement
neurogenic atrophy of skeletal muscles
- anterior ventral horn

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

protein aggregation

A

genetic mutation or oxidation causes protein folding–>cytoplasmic accumulation and aggregation
TDP-43

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

pathological protein in MND

A

TDP-43

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

neuroinflammation

A

proliferation and activation of astrocytes and microglia

reactive gliosis, leads to glial scar (sclerosis)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

crossover with dementia

A

many MND patients, also experience FTD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

ALS-FTD spectrum

A

mutations that are more likely to result in symptoms of ALS or FTD
e.g . C9ORF72- 50% of either

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

sporadic MND

A

90% of MND cases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

possible contributing factors to sporadic MND

A

genetic background, somatic mutation, development

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

possible environmental factors for sporadic MND

A

smoking, chemical exposure, deployment, virus (integrate into DNA), blue-green algae, elite sports

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

sporadic MND hypothesis

A

6 factors required to initiate disease process, towards end, rapid motor neuron loss

17
Q

familial MND

A

10% of cases, 25 genes identified so far

18
Q

6 implicated mechanisms in pathophysiology of MND

A

oxidative stress, mito dysfunction, excitotoxicity, protein aggregation, impaired axonal transport, neuroinflammation

19
Q

oxidative stress

A

ROS generation not controlled, reduced capacity to remove, oxidative damage

20
Q

mito dysfunction

A

ROS accumulation, mtDNA and protein damage, mito calcium homeostasis disrupted, apoptotic cell death

21
Q

excitotoxicity

A

elevated synaptic glumate levels and receptors on motor neurons
- excessive stimulation–>calcium influx–>neuronal injury

22
Q

protein aggregation

A

TDP-43

-defects in protein degradation e.g. ubiquitin proteasome system, autophagy

23
Q

impaired axonal transport

A

axonal transport of cargoes for motor neurons that are highly polarised and long projection cells
- slowing of axonal transport–>deficiency of cargoes in axons and distal synapses

24
Q

neuroinflammation

A

innate- CNS resident astrocyte and microglial activation
adaptive- peripheral lymphocytes e.g. T cells into CNS
- production of pro-inflammatory cytokines

25
Q

2 clinically approved drugs

A

Riluzole

edaravone

26
Q

riluzole

A

glutamate receptor antagonist

  • attentuates excitotoxicity
  • blocks Na channels, enhance glutamate uptake
27
Q

edaravone

A

antioxidant and free radical scavenger (removes ROS)

-may slow physical decline when administered early

28
Q

2 cell therapies using stem cells

A
  1. replace lost neurons- but can’t reconnect motor neuron circuit
  2. support surviving motor neurons- effectiveness not demonstrated